Project Grant R01HL188011
Award Date 8/15/26
Completion Date 4/30/30
Dollars Obligated $767K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $744,157 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of lung cell fate determination in the conducting airways and alveolar epithelium. The research investigates how SOX9+ progenitors produce SOX2+ cells to form conducting airways and generate AT1/2 cells to form alveoli, with emphasis on Hippo signaling and...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $778,127 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL180797) to enhance lamellar body function via LRRK2 inhibition and reduce respiratory distress syndrome severity in preterm newborns. The research investigates leucine-rich repeat kinase 2 (LRRK2) inhibition as a novel therapeutic approach to enhance endogenous surfactant production in...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco (UCSF) $297,806 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the senescence marker P16INK4A in alveolar epithelial stem cells during injury-triggered differentiation. The research examines how alveolar type 2 cells (AT2s), which serve as lung stem cells, differentiate into alveolar type 1 cells and how the...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $778,504 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate molecular mechanisms controlling lung capillary speciation, plasticity, and function during early postnatal development. The research examines how distinct subtypes of lung capillary endothelial cells—CAP1 and CAP2—contribute to alveolar formation and repair after injury during...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 2, 2026, to support research on the role of subpleural fibroblasts in pulmonary fibrosis progression. The funded research investigates idiopathic pulmonary fibrosis (IPF), which begins with scar tissue buildup at the lung edges and advances centrally. The project applies lineage tracing, mouse modeling, and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $1,231,094 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the molecular mechanism of pediatric interstitial lung disease caused by surfactant protein C (SFTPC) gene mutations and advance targeted therapies. The University of Pennsylvania research team, led by Dr. Jeremy Katzen, will develop and leverage in vivo mouse models and human induced...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $174,744 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support career development training in synthetic biology methods and research on pulmonary fibrosis mechanisms. The award funds a K08 mentored research career development grant led by principal investigator Dr. Anjali Jacob, MD/PhD, a pulmonary and critical care physician at UCSF. The...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,265,021 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The research investigates pathologic fibroblast subsets unique to silicosis, a chronic and potentially fatal fibrotic disease caused by inhalation of crystalline silica. Recent worldwide outbreaks among workers cutting engineered stone for countertops have underscored the need to...